Drug intelligence / Profile preview

Debio 1455

Development stage: Unknown
Lead developer: Debiopharm
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

Debio 1455 is an investigational microbiome remodeling therapeutic being developed by Debiopharm for the treatment of Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. The drug utilizes a novel approach to selectively target and eliminate disease-causing intestinal bacteria while preserving the natural balance and integrity of the gut microbiota. By remodeling the microbiome rather than employing broad-spectrum antibiotics or systemic immunosuppressants, Debio 1455 aims to restore intestinal homeostasis and provide a more targeted treatment option for chronic inflammatory gut conditions. As of early 2024, the compound is in Phase 1 clinical development.

Beyond the preview

Go deeper on Debio 1455.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 1455.

Explore the full profile